Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRQOKB)

Drug Name

2-(biphenyl-4-yl)vinylboronic acid Drug Info

Synonyms

352530-23-5; trans-2-(4-Biphenyl)vinylboronic acid; (2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid; (E)-(2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid; AC1O0CFW; Alkenylboronic Acid, 22; 4-Phenylstyrylboronic acid; CHEMBL453758; SCHEMBL2910475; SCHEMBL12260418; C14H13BO2; BDBM26143; DTXSID30421729; ZINC169870786; AKOS015893176; FCH5518572; AB21449; RTR-014581; KB-61854; BBV-43957496; ACM352530235; OR360465; AX8240126; [(E)-2-(4-phenylphenyl)ethenyl]boranediol; V5431; [(E)-2-(4-phenylphenyl)ethenyl]boronic acid; B-4710; I04-2357

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6011033
CAS Number: CAS 352530-23-5
TTD Drug ID: DMRQOKB

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[3]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[4]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[5]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[6]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[7]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[8]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[9]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[10]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[10]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[11]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[12]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[12]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[13]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[12]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[14]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[15]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[16]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[14]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[1]
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5.
2	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
3	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
4	The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
7	The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
8	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
10	A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
11	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
12	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
14	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
15	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
16	Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
17	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.